Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations

摘要: Background: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) predict better outcome to EGFR tyrosine kinase inhibitors. The most common are exon 19 deletions (most frequently E746–A750) and L858R point mutation 21. Here, we evaluated the accuracy of novel mutation-specific antibodies a Japanese cohort with NSCLC compared direct DNA sequencing clinical outcome. Materials Methods: Immunohistochemistry (IHC) using specific for E746–A750 was performed on tissue microarrays tumors from 70 gefitinib treated patients. Extracted sequenced mutational analysis exons 18 Results: showed 41 patients (58.6%) (25.7%), 11 (61%) had deletion range 12 (17.1%) 21 (L858R). IHC showed, mutations, sensitivity (81.8 75%), specificity (100 96.6%), positive predictive value 81.8%), negative (96.7 94.9%). Analysis objective response rates survival were not correlated staining, although combined staining nonsignificant trends toward overall mutations. Conclusions: have high predefined EFGR may be suitable screening these However, results require further analyses before excluding EGFR-targeted therapy.